Abstracts tagged "Biomarkers"

Abstract Number: 511 • 2018 ACR/ARHP Annual Meeting
Identifying Vulnerable Plaque in Rheumatoid Arthritis Using Novel Microbubble Contrast-Enhanced Carotid Ultrasonography and Serum Biomarkers of Inflammation and Atherosclerosis
Linda F. Wang¹, Yaming Li², Douglas Landsittel³, Suresh R. Mulukutla⁴, Steven Reis⁵, Marc Levesque⁶, Donald M. Jones⁷, Rachel Gartland⁶, Jennifer Avolio⁸, Ali Hakim Shoushtari⁸, Flordeliza Villanueva⁵, Larry W. Moreland⁹ and Kimberly P. Liang⁶, ¹School of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Biostatistics, University of Pittsburgh, Pittsburgh, PA, ³Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁵Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) patients have an elevated risk of cardiovascular (CV) disease unexplained by traditional CV risk factors. Markers of systemic inflammation, including those…
Abstract Number: 924 • 2018 ACR/ARHP Annual Meeting
10X Genomics-Based Single-Cell RNA-Seq and Low Input RNA-Seq Identify a Transcriptional Landscape Supporting Interferon in the Pathogenesis of Autoimmune-Associated Congenital Heart Block
Hemant Suryawanshi¹, Jill P. Buyon², Miao Chang², Thomas Tuschl¹ and Robert M. Clancy², ¹Howard Hughes Medical Institute and The Rockefeller University, New York, NY, ²NYU School of Medicine, New York, NY
Background/Purpose: Towards understanding the molecular mechanisms that link maternal anti-Ro antibodies to the development of conduction system disease in a second trimester fetus, single cell…
Abstract Number: 1370 • 2018 ACR/ARHP Annual Meeting
Detection of an Autoantibody Profile to Characterize Patients with Early (Pre-symptomatic) Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Maria Camacho¹, Florencia Picchi¹, Ignacio Rego-Pérez², Raul Manzano-Román³, Valentina Calamia¹, Jennifer VanDuine⁴, Ji Qiu⁴, Cristina Ruiz-Romero⁵, Manuel Fuentes³, Joshua LaBaer⁴ and Francisco J Blanco⁶, ¹Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ²Rheumatology Research Group, Genomic Unit, INIBIC-CHUAC, A Coruña, Spain, ³Department of Medicine and General Cytometry Service-Nucleus, Proteomics Unit, Cancer Research Center (IBMCC/CSIS/USAL/IBSAL), Salamanca, Spain, ⁴Virginia G. Piper Center for Personalized Diagnostics, Biodesign Institute (ASU), Tempe, AZ, ⁵Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁶Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Although osteoarthritis (OA) has not been considered as an autoimmune disorder, there are increased evidences of the role of the immune system in OA…
Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting
Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Masataka Kuwana², Ning Li³, Julio Charles⁴, Faye N. Hant⁵, Galina S. Bogatkevich⁶, Tanjina Akter⁶, Michael Roth⁷, Hyun J. Grace Kim⁸, Jonathan Goldin⁹, Dinesh Khanna¹⁰, Philip J. Clements¹¹, Daniel E. Furst⁷, Robert Elashoff¹², Rick Silver¹³ and Shervin Assassi¹⁴, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, ¹⁰Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Medicine, University of California, Los Angeles, Los Angeles, CA, ¹²University of California, Los Angeles, Los Angeles, CA, ¹³Rheumatology, Medical University of SC, Charleston, SC, ¹⁴University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…
Abstract Number: 2147 • 2018 ACR/ARHP Annual Meeting
Associations between Current Cigarette Smoking and SLE-Related Cytokine and Chemokine Biomarkers Among U.S. Female Nurses without SLE
Cianna Leatherwood¹, Xinyi Liu¹, Susan Malspeis², Andrea Roberts³, Jeffrey A. Sparks¹, Elizabeth Karlson¹, Candace H. Feldman¹, Judith A. James⁴, Laura Kubzansky⁵ and Karen Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA, ⁴OMRF & OUHSC, Oklahoma City, OK, ⁵Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Current cigarette smoking and recent cessation (within 4 years), compared to no smoking or remote cessation, have been associated with increased anti-dsDNA+ SLE…
Abstract Number: 570 • 2018 ACR/ARHP Annual Meeting
Evaluation of CXCL13, sICAM1, MMP-3 and S100A8/A9 As Serum Biomarkers in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab
D. James Haddon, Thierry Sornasse, Michael J. Townsend, Jinglan Pei and Margaret Michalska, Genentech, Inc., South San Francisco, CA
Background/Purpose: Serum levels of C-X-C motif chemokine ligand 13 (CXCL13) and soluble intercellular adhesion molecule-1 (sICAM-1) have been associated with outcomes in patients with rheumatoid…
Abstract Number: 961 • 2018 ACR/ARHP Annual Meeting
The Association of Biologic Drug-Levels with Infection Risk: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Meghna Jani¹, William G Dixon¹, Mark Lunt¹, Diederik De Cock¹, John Isaacs², Ann Morgan³, Kath Watson¹, Anthony G. Wilson⁴, Anne Barton^5,6 and Kimme L. Hyrich^1,5, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁴UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland, ⁵National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom
Background/Purpose: High dose tumour necrosis factor inhibitor (TNFi) drugs are associated with an increased serious infection (SI) risk[1]. It is feasible that high biologic…
Abstract Number: 1417 • 2018 ACR/ARHP Annual Meeting
Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes
Giulia Marucci¹, Ivan Caiello², Manuela Pardeo¹, Virginia Messia¹, Giusi Prencipe¹, Antonia Pascarella¹, Fabrizio De Benedetti³ and Claudia Bracaglia¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Increased ferritin is considered biomarker highly suggestive of primary and secondary HLH and it is one of the HLH-2004 diagnostic and MAS guidelines (1,2),…
Abstract Number: 1907 • 2018 ACR/ARHP Annual Meeting
High Serum Adiponectin Associates with the Incidence of Rheumatoid Arthritis in Obese Subjects
Cristina Maglio¹, Yuan Zhang², Christian Herder³, Anna Rudin⁴ and Lena Carlsson⁵, ¹Dep. of Rheumatology and Inflammation Research and Wallenberg Centre for Molecular and Translational Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Dep. of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ³German Diabetes Center, Düsseldorf, Germany, ⁴Dept of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁵Department of Molecular and Clinical Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Adiponectin, a cytokine mainly produced by the adipose tissue, plays an important role in several metabolic and inflammatory processes. In obese subjects, serum adiponectin…
Abstract Number: 2682 • 2018 ACR/ARHP Annual Meeting
Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus
Yu-Min Kuo^1,2, Jenhao Chen³, Jean-san Chia⁴, Chiau-jing Jung⁵ and Song-Chou Hsieh⁶, ¹Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan, ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ³Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital,Yunlin branch, Yunlin County, Taiwan, ⁴Graduate Institute of Immunology, National Taiwan University College of Medicine, Taipei, Taiwan, ⁵Department of Microbiology and Immunology, School of Medicine,, College of Medicine, Taipei Medical University, Taipei, Taiwan, ⁶National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Streptoccocal infections can cause rheumatic fever sharing clinical presentations similar to SLE. Whether oral commensal streptococci could induce cross-reactive and pathogenic antibodies remained unknown.…
Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
Ted R. Mikuls¹, Amrita Bath², Bryant R. England³, Michael J. Duryee⁴, Carlos D. Hunter⁴, Joel Kremer⁵, Dimitrios A. Pappas^6,7, William H. Robinson⁸, Jeffrey R. Curtis⁹ and Geoffrey M. Thiele¹⁰, ¹Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Albany Medical Center, Albany, NY, ⁶Columbia University, New York, NY, ⁷Corrona, LLC, Waltham, MA, ⁸Stanford University, Palo Alto, CA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents. As previous studies have…
Abstract Number: 989 • 2018 ACR/ARHP Annual Meeting
Reduction of Serum IL17F and IL22 By IL23p19 Blockade with Guselkumab Is Associated with Improvement in Joint Symptoms in Psoriatic Arthritis
Qingxuan Song, Matthew Loza, Karen Leander, Brittney Scott, Patrick Branigan and Kristen Sweet, Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that binds to the p19 subunit of IL23. In a recent Phase 2 study, GUS demonstrated…
Abstract Number: 1426 • 2018 ACR/ARHP Annual Meeting
The Utilization of S100 Proteins Testing in Pediatric Rheumatology Patients in a Tertiary Care Institution and Implications for Care
Najla Aljaberi¹, Angela Merritt², Alexei Grom¹, Grant Schulert³, Jennifer L. Huggins⁴, Michael Henrickson⁵ and Hermine I. Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children’s Medical Center, Cincinnati, OH
Background/Purpose: S100 proteins are calcium-binding proteins of increasing value as biomarkers in various inflammatory conditions (e.g. autoinflammatory diseases, vasculitides, inflammatory bowel disease). The two highly…
Abstract Number: 1973 • 2018 ACR/ARHP Annual Meeting
Leveraging Publicly Available Gene Expression Data and Applying Machine Learning to Identify Novel Biomarkers for Rheumatoid Arthritis
Dmitry Rychkov¹, Marina Sirota² and Cindy Lin³, ¹Institute for Computational Health Sciences, University of Calfornia, San Francisco, San Francisco, CA, ²Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ³Stanford, Stanford, CA
Background/Purpose: Diagnosis and monitoring the disease progression of RA is challenging requiring a combination of imaging techniques and blood tests. There is currently no biochemical…
Abstract Number: 2690 • 2018 ACR/ARHP Annual Meeting
Potential Markers of Skin Involvement in Systemic Sclerosis
Radim Becvar¹, Hana Storkanova², Barbora Sumova¹, Maja Spiritovic¹, Sabina Oreska², Ladislav Šenolt¹ and Michal Tomcik², ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Skin fibrosis is a hallmark of systemic sclerosis (SSc). There are no widely accepted biomarkers of skin involvement in this condition. Several serum or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].